Aceso Life Science Group Limited

As of March 31, 2026, Aceso Life Science Group Limited carries a market capitalization of 1.05B, placing it among publicly traded companies globally. Its enterprise value stands at 1.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Aceso Life Science Group Limited has 8.86B shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Aceso Life Science Group Limited maintains a current ratio of 2.28, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 21, 2026, Aceso Life Science Group Limited's stock has gained approximately 27.27% over the past 52 weeks. The 50-day moving average sits at 0.14, while the 200-day moving average is 0.12.

As of March 31, 2026, Aceso Life Science Group Limited holds 326.00M in cash and equivalents against 1.21B in total debt, resulting in a net debt position of 1.08B. Total book value stands at 457.00M, with working capital of 240.00M providing operational flexibility.

Aceso Life Science Group Limited's most recent stock split took place on July 12, 2017 with a 6:7 split ratio.